





CONTENTS

1. **Company Overview**
2. **Business Overview**
 - 1) **Glucose Monitoring Business**
 - 2) **CGM Future Plan**
 - 3) **POCT Business**
3. **Appendix**

DISCLAIMER

This presentation contains certain forward-looking statements that are derived from the company's forecasts, business plans and strategy. While these statements represent our current judgment on future prospects, actual results may differ materially due to various factors such as modification of business plans and strategies, delays in bringing products to market, changes in regulations and so forth.

Although i-SENS, Inc. has taken great care in preparing the material, the company does not guarantee the accuracy or completeness of the material in this presentation.

THIS MATERIAL IS NEITHER AN OFFER NOR INTENDED AS INVESTMENT, FINANCIAL, LEGAL, ACCOUNTING, TAX OR ANY OTHER ADVICE.

All materials have been prepared in accordance with K-IFRS. All figures in USD are converted using the exchange rate of 1 USD = 1,400 KRW.

Sensing Ahead, Caring More



1. Company Overview

2. Business Overview

- 1) **Glucose Monitoring Business**
- 2) **CGM Future Plan**
- 3) **POCT Business**

3. Appendix


1. Market Overview: In Vitro Diagnostics

In Vitro Diagnostics (IVD)



The Largest Market in Medical Devices

IVD by Segment



i-SENS Business Segments

Glucose Monitoring

• Blood Glucose Monitoring (BGM)

• Continuous Glucose Monitoring (CGM)

POCT (Point-of-Care Testing)

i-SENS Sales Ratio

83%

2%

15%

Source: Grand View Research (2024)

* Based on 2024 revenue

2. i-SENS Product Portfolio

Glucose Monitoring

BGM (Blood Glucose Monitoring)



Test Strip



Meter

CGM (Continuous Glucose Monitoring)



Launched in September 2023

POCT (Point-of-Care Testing)

POCT Devices



BGM for Hospital Use



HbA1c Analyzer



Blood Electrolyte Analyzer



Blood Gas Analyzer



PT/INR* Analyzer



Immunoassay Analyzer

* PT/INR(Prothrombin Time and International Normalized Ratio)

3. History: Steady and Stable Growth

Founded in 2000

Developed CareSens in 2003


Established Wonju Factory in 2007

i-SENS Consolidated Revenue (\$ Million)



i·sens

4. Business Structure and Global Partners



Sensing Ahead, Caring More




1. Company Overview
2. Business Overview
 - 1) Glucose Monitoring Business
 - 2) CGM Future Plan
 - 3) POCT Business
3. Appendix

1. Diabetes Population


Increasing Diabetes Population

Diabetes Patients Forecast



Type
of
Patients

Type
of
Devices



Source: IDF(International Diabetes Federation), i-SENS Analysis


2. New Marketing Message

"BY YOUR SIDE" — supporting users in managing their health.



3. Glucose Monitoring (CGM VS BGM)


Glucose Level Continuously Measured on a Real-time Basis



Type	BGM	CGM
How it works	Measures glucose level in the blood of fingertip	Measures glucose level of interstitial fluid through sensor inserted beneath the skin
Target users	All types of diabetes patients (Type 1&2, gestational diabetes patients)	Type 1 and severe type 2 diabetes patients
Where to use	Fingertip	Upper arm
Measurement sample	Capillary blood	Interstitial fluid (No blood drawn)
Replacement period	Disposable single-use strip	15 days per sensor
Strengths	High accuracy and reasonable price	Diabetes management easier, alarm function for hypoglycemia/hyperglycemia, less pain than BGM, simple data sharing
Challenges	Frequent measurements, penetration pain, hypoglycemia shocks	High price, skin irritation, lower accuracy compared to BGM

4. CGM Mid-Term Goal

In line with competitors' sales trends, i-SENS is pursuing a 10% market share by 2030, supported by FDA approval anticipated in 2027.



5. CGM Business Overview

CareSens Air launched in South Korea (Sep 2023) and is expanding globally

Key Milestones

South Korea launch

Sep 2023

CE MDR approval

Mar 2024

MFDS approval update
(CareSens Air Upgrade)

Jan 2025

Feb 2024

Linked with
Kakao Healthcare
'PASTA'

May 2024

Domestic launch (Handok PL)
Overseas rollout

Mar 2025

CE MDR approval update

Business Status

- CareSens Air upgrade launch:
 - South Korea: Mar 2025
 - Europe: Apr 2025
- Reimbursement in South Korea, Hungary, Estonia, UK

CareSens™ Air

6. CGM Sales & Marketing Plans

Supplying CGM Products through Various Sales Channels with CareSens Air and Private Label Brands



1

CareSens™ Air

- Existing BGM distributors
- Digital health service company **kakao**healthcare
- Hospital and pharmacy chains
- Online malls
- Corporations & health insurance companies

2


PL Brands

PRIVATE
LABEL

- Global medical device manufacturer / pharmaceutical company
- Insulin supply device manufacturer
- Global medical device distributor
- Digital health product & service provider

7. CGM Global Expansion Plan

Leveraging domestic CGM experience to accelerate global expansion



8. Next-Gen Upgrade: Comparing CareSens Air & Air 2




	CareSens Air	CareSens Air 2	Comparison
Sensor Size	35.2 x 19.2 x 5.0 mm	23.6 x 15.8 x 2.9 mm	70% reduction
Sensor Weight	Approx. 4.3g	Approx. 1.3g	70% reduction
Applicator Size	51.8 x 40.8 x 71 mm	50.5 x 40.0 x 73.5 mm	Similar
Applicator Weight	Approx. 74 g	Approx. 45 g	40% reduction
Useful Life	15 days	18 days	20% Increase
Warm-up Time	30 minutes	20 minutes	10 min reduction
Sensor Transmission Range	6m	10m	67% increase
Data Transfer Interval	Every 5 minutes	Every 1 minute	-
Power Button	Yes	No	Removed

9. Product Comparison: i-SENS vs. Competitors

	i.sens CareSens Air	i.sens CareSens Air 2 (planned)	Competitor D7	Competitor F3
Sensor Size	35.2 x 19.2 x 5.0 mm	23.6 x 15.8 x 2.9 mm	24 × 27.3 × 4.6 mm	21(dia) x 2.9 mm
Useful Life	15 days	18 days	10 days	14 days
Calibration	supports calibration if needed	supports calibration if needed	Optional calibration	Not available
Warm-up Time	30 minutes	20 minutes	30 minutes	1 hour
Data Transfer Interval	Every 5 minutes	Every 1 minute	Every 5 minutes	Every 1 minute


10. CareSens Air Upgrade: Product Roadmap

Continuous improvements to strengthen market competitiveness




11. CareSens Air 2: Product Roadmap

Targeting domestic launch in Q3 2026, global launch in Q1 2027



12. BGM Strip & CGM Sensor Production Capacity

Highly Efficient Manufacturing Facilities with Annual Capacity of **2.5 billion BGM Strips** and **500,000 CGM Sensors (2024)** → **2 million in 2025 with automatization**



※ Gross Production Capacity : Average daily production \times No. of working days \times No. of operating months ※ Based on one shift (8 working hours/day)

13. CGM Production Line Investment Plan

Automated CGM Production Line at Songdo Factory 2 – Planning & Design Phase for Installation

Songdo
Factory



CGM Production Line (Present)

- Initial CGM production volume
- Semi-automated production line
- Annual capacity: 500k sensors
- Installation cost: approx. KRW 5 billion

Songdo
Factory 2



CGM Production Line (Plan)

- Large-scale CGM production (scheduled for June 2025)
- Automated production line (design and equipment order completed)
- Annual capacity: 1.5 million sensors (based on one production line)

14. CGM Future Plans: 2025 Schedule

	Q1	Q2	Q3	Q4
BGM	<ul style="list-style-type: none"> Start localized production in Algeria (annual production capacity: 200 million strips) 	<ul style="list-style-type: none"> Launch of embecta PL brand 	<ul style="list-style-type: none"> Clinical trial of next-generation blood glucose strip (hospital use) 	<ul style="list-style-type: none"> Expansion of localized production business (Morocco, Egypt, Saudi Arabia, etc.)
CGM	<ul style="list-style-type: none"> Overseas insurance registration in progress Participating in tenders: (Italy & Spain) 	<ul style="list-style-type: none"> Negotiating CGM PL deals with multiple global partners Launch of Samsung 'My Health Phone' 	<ul style="list-style-type: none"> Launch of CGM receiver Launch of AgaMatrix PL brand (UK) 	
CGM R&D	<ul style="list-style-type: none"> Start clinical trial for ages 2+ of CareSens Air (Germany) CareSens Air approval update for upgraded version (Korea MFDS & Europe CE) Approval for CGM receiver and sensor for professional-use Korea MFDS approval for watch compatibility 	<ul style="list-style-type: none"> Start type testing (China) Submission of PMDA approval application (Japan) 		<ul style="list-style-type: none"> Completion of clinical trial for CareSens Air 2 (Korea) Completion of FDA pivotal clinical trial (US) Submission of type testing and clinical trial application (China)
Production	<ul style="list-style-type: none"> Start localized production for BGM meters (Vietnam & China) 	<ul style="list-style-type: none"> Start operation of CGM production line at Songdo Factory 2 KGMP certification for CGM automated line 	<ul style="list-style-type: none"> GMP certification for CGM automated line 	
Other	<ul style="list-style-type: none"> Start construction of Magok R&D Center Share buyback Resolution to adopt electronic voting system 	<ul style="list-style-type: none"> Buyback and retirement of treasury shares 		


Sensing Ahead, Caring More



1. **Company Overview**
2. **Business Overview**
 - 1) **Glucose Monitoring Business**
 - 2) **CGM Future Plan**
 - 3) **POCT Business**
3. **Appendix**


1. Product Experience: 1) Integration of BGM & CGM

Integrated app for CGM and BGM synergy




2. Product Experience: 2) Expanded Service Integration

Expanded care through CGM data integration



3. Business Growth Strategy: 1) Product Supply via Partner Network

Delivering CareSens Air through partner network powered by CGM data connectivity



4. Business Growth Strategy: 2) Global Sales & Manufacturing

Expand global supply through local sales and manufacturing partners


Sales

CareSens™ Air



CareSens Air or private label supply based on regional demand

Manufacturing



Localized automated production by country

Sensing Ahead, Caring More



1. **Company Overview**
2. **Business Overview**
 - 1) **Glucose Monitoring Business**
 - 2) **CGM Future Plan**
 - 3) **POCT Business**
3. **Appendix**

1. i-SENS POCT Strategies

Hospital Market Expansion and Professionals' Trust

POCT (Point-of-Care Testing)

- POCT means tests performed at the time and place of patient care, providing faster results than central lab




POCT



Central Laboratory

i-SENS POCT Strategies

- Enhance brand value through offering our reliable products to professionals



i-SENS POCT Highlights

- Our devices utilize consumables (such as sensor, cartridge, reagents ,etc) -> Continuous profit



2. POCT: Blood Electrolyte / Gas Analyzer

The market demand is changing from medium/large devices to small devices

Blood Gas Analyzer Market

- Global market size : \$1.4 billion*
(2nd largest market in POCT)
- Intended use : To test any imbalance in blood gases such as pO_2 , pCO_2 and pH
- The imbalance is shown as Kidney disease, heart disease, respiratory disorder, shock, and etc.
- Usage: Hospitals, intensive care units, emergency rooms, and operating rooms

Blood Electrolyte Analyzer Market

- Intended use : To test the level of body hydration, muscle & nerve action, oxygen supply, and etc.
- Usage: General clinic, hospital, and etc.

Blood Electrolyte Analyzer



- Launched in February 2009
- #1 in Korea (Installed base)
- Measured components: Hct, Na, K, Cl (Existing product)
- + Ca, Mg (In development)

Blood Gas Analyzer



- Launched in 2020
- Measured components: pH, pCO_2 , pO_2 , Hct, Na, K, Cl, iCa, Glucose, Lactate

* Source: TriMark Publications Point of Care Diagnostic Testing World Markets (2013)

3. POCT: High-value Diagnostic Devices for Professionals

POCT Portfolio Diversification & Driving Growth in Hospital BGM

Diabetes Care for Hospital Use

HbA1c Analyzer



ACR Cartridge



- HbA1c test: Measurement of glycated hemoglobin level to diagnose diabetes
- Single test detects the average blood glucose level during past three months
- All-in-one cartridge, fast and accurate results
- Global HbA1c market size: \$474M*

BGM For Hospital Use



- Easy hospital data management: Real-time transmission through Wi-Fi and USB, software auto-update, etc.



Coagulation Analyzer

PT/INR Analyzer



- Product of CoaguSense, an i-SENS subsidiary in the US
- Prothrombin Time tests (PT tests) are widely used to monitor the therapeutic range of a long-term anti-coagulant such as warfarin

• CoaguSense Highlights

PT 2 system have received 510(k) clearance from the U.S.FDA in 19Q1

* Source: Global POC Glycated Hemoglobin Analyzer Market Research Report (2018)

4. POCT: Immunoassay Analyzer

Smart Integration: Does Not Require any Pretreatment of the Whole Blood

Background

- Immunochemical sensor measures antigen-antibody reaction for proteins
- A platform which measures the important cardiac markers in emergency care
- Target market: Large- and medium-sized hospitals & clinics
- Competitors: Radiometer, Mitsubishi and Siemens

Features

- Internal centrifuge process eliminates hematocrit bias → As accurate as laboratory test
- Random access up to four individual tests → Suitable for emergency care
- Compact size compared to other products
- Easy to expand market with infectious diseases



Sensing Ahead, Caring More



1. **Company Overview**
2. **Business Overview**
 - 1) **Glucose Monitoring Business**
 - 2) **CGM Future Plan**

3. Appendix

Appendix 1. Company Profile



Appendix 2. Manufacturing supported by strong R&D

Investing in Biosensor R&D

Co-founders Profile



Geun Sig Cha (Chairman, CEO)

- BS, MS Korea University, Dept. of Chemistry
- PhD, University of Michigan
- '91~'15 Professor at Kwangwoon University, Dept. of Chemistry
- Present: Emeritus Professor at Kwangwoon Univ.
- '00~Present: i-SENS, Inc., CEO, Chairman
- '11 Ministerial Citation Award for Korea's Startup Exhibition (Ministry of Knowledge Economy)
- '14 Ministerial Citation of Merit Award for Medical Device Industry (Ministry of Health and Welfare)
- '16 Presidential Citation of Merit for Electronics& IT Day (Ministry of Trade, Industry and Energy)




Hakhyun Nam (President, CEO)


- BS, Seoul National University, Dept. of Chemistry
- PhD Michigan State University
- '92 ~'15 Professor at Kwangwoon University, Dept. of Chemistry
- Present: Emeritus Professor at Kwangwoon University.
- '00 ~ Present : i-SENS, Inc., CEO, President
- '08 Citation of the excellent researcher for R&D in health and medical science technology (Minister of Health and Welfare)
- '11 Citation of Merit Award for Industrial-education Cooperation
- '11 Citation of Merit Award for Industrial Technology
- '19 KITA's top export award (Ministry of Trade, Industry and Energy)
- '19 Citation of Science, Information and Communication Day (Prime Minister)

R&D Expenses

- Ratio of R&D expenses to revenue
- R&D investments (\$ million) (Parent company basis)



Number of Employees



(As of December 31st, 2024)